Endocrine

Paget disease of bone: diagnosis and treatment

Clinical Overview and When to Suspect Paget Disease of Bone

— Results in enlarged, weakened, mosaic-pattern woven + lamellar bone prone to deformity, fracture, and arthritic complications

— Typically polyostotic but can be monostotic; lesions do not migrate — once established in a bone, the disease stays in that bone

— Prevalence rises sharply after age 55; rare under age 40

— More common in patients of Northern European ancestry (UK, Australia, New Zealand, US Northeast); incidence has been declining in recent decades

— Family history present in 15–40%; SQSTM1/p62 mutations are the most consistent genetic association

— Possible (debated) paramyxovirus trigger

— Incidental isolated elevation in alkaline phosphatase (ALP) in an older adult with normal LFTs, normal calcium, normal phosphate — this is the classic stem

— Bone pain that is deep, dull, worse at night and at rest (unlike OA which improves with rest)

— New bony deformity: bowed tibia, frontal bossing, increasing hat size, kyphosis

— Conductive (or mixed) hearing loss in an older adult — from temporal bone involvement

— Pathologic or low-energy fracture, especially through a chalk-stick transverse femoral or tibial fracture

— Warmth over a bony prominence (hypervascularity)

Board pearl: In a Step 3 stem, an asymptomatic 68-year-old with isolated ALP 3–4× ULN, normal GGT, normal calcium, and a "rim of sclerosis" on hip film = Paget until proven otherwise. The very next steps are GGT/LFTs to confirm bony origin, then plain radiographs of symptomatic sites and a whole-body bone scan to map disease extent before treatment decisions.

Definition: Paget disease of bone (PDB, osteitis deformans) is a focal disorder of accelerated, disorganized bone remodeling driven by hyperactive, multinucleated osteoclasts followed by exuberant but architecturally chaotic osteoblastic bone formation.

Epidemiology:

When to suspect on Step 3:

Common sites (mnemonic — "PSF-TLH"): Pelvis (most common), Spine (lumbar), Femur, Tibia, Lumbar vertebrae, Humerus, Skull

Presentation Patterns and Key History

— Detected via incidental ALP elevation on routine chemistry or incidental radiographic finding (pelvis film for hip pain, lumbar spine for back pain)

— Step 3 stems love this: "routine labs show ALP 412 U/L, otherwise normal" in a 65-year-old

— Pelvis/hip: deep aching pain, often misattributed to OA; secondary hip OA from acetabular protrusion is the most common cause of pain

— Femur/tibia: anterolateral bowing ("saber shin" of tibia), gait abnormality, stress fractures on the convex (tensile) surface

— Skull: headache, enlarging hat size, frontal bossing, platybasia with basilar invagination → brainstem compression, hydrocephalus

— Temporal bone: mixed conductive + sensorineural hearing loss, tinnitus, vertigo (cochlear capsule + ossicle involvement)

— Spine: back pain, spinal stenosis from vertebral enlargement, rarely cord compression from vascular steal (not just mass effect)

— Jaw (maxilla > mandible): dental malocclusion, loose teeth, dentures no longer fit

— Character of pain: constant, worse at night, worse with weight bearing, not relieved by rest (vs OA)

— New-onset hearing loss, headache, dizziness

— Change in hat or denture fit, change in shoe wear pattern from bowing

— Family history of Paget, early hearing loss, or bone deformity

— Ancestry (Northern European)

— Medication review: bisphosphonate use for osteoporosis may have masked or treated subclinical disease

— Sudden increase in pain in a known pagetic bone → sarcomatous transformation (osteosarcoma, <1%)

— New neurologic deficit → cord/cranial nerve compression

— Polyuria, polydipsia, confusion → immobilization hypercalcemia

Key distinction: OA pain improves with rest and worsens with activity; Paget pain is worse at rest and at night, and the bone itself feels warm to palpation because of hypervascularity — a feature OA never produces.

Asymptomatic presentation (70–90%):

Symptomatic patterns by anatomic site:

High-yield history questions:

Red-flag symptoms suggesting complications:

Physical Exam Findings and Functional Assessment

— Frontal bossing, enlarged cranium, prominent supraorbital ridges

— Hearing aid in place (clue), patient leans forward to hear

— Kyphosis, loss of height, simian (ape-like) posture from spinal + femoral bowing

— Anterolateral tibial bowing ("saber shin"); lateral femoral bowing ("shepherd's crook")

— Leg-length discrepancy from femoral involvement

— Increased warmth over affected long bones — pathognomonic-feeling sign reflecting hypervascularity (AV shunting within remodeled bone)

— Tenderness over pelvis, tibia, or skull

— Palpable bony enlargement; pelvic asymmetry on hip exam

— Auscultation: occasional bruit over a vascular pagetic skull lesion

— Cranial nerves: CN II (optic foramen compression → vision loss), CN VII (facial palsy), CN VIII (hearing loss, vertigo), CN V

— Long-tract signs: hyperreflexia, Babinski, gait ataxia → platybasia/basilar invagination or spinal stenosis

— Sensory level if cord compression suspected

— Cerebellar testing — posterior fossa crowding

— With >35–40% skeletal involvement, AV shunting can cause high-output heart failure

— Look for wide pulse pressure, bounding pulses, warm extremities, elevated JVP, S3, displaced PMI

— Bedside: warm skin over bones + signs of volume overload should trigger TTE and BNP

— Antalgic gait from hip/knee secondary OA

— Trendelenburg from acetabular protrusion

— Fall risk screen (Timed Up and Go) — critical in this older cohort

CCS pearl: On a CCS case of suspected Paget with a bowed femur, your physical exam orders should explicitly include "skin temperature over affected bone," "neurologic exam including cranial nerves," and "cardiovascular exam" — these three findings change management urgency (high-output failure → admit; CN deficits → urgent imaging + neurosurgery consult).

General inspection:

Palpation and local exam:

Neurologic exam (always document):

Cardiovascular assessment:

Functional/gait assessment:

Diagnostic Workup — Initial Labs and Imaging

— Serum total alkaline phosphatase (ALP): elevated in 85% of active disease; magnitude correlates with extent and activity. Often 2–10× ULN

— GGT or 5'-nucleotidase: order to confirm ALP is bony, not hepatic, in origin (normal GGT → bone source)

— Calcium and phosphate: characteristically normal at baseline (key feature distinguishing from hyperparathyroidism and osteomalacia)

— 25-OH vitamin D: must check and repletε before bisphosphonate therapy to prevent hypocalcemia

— Creatinine/eGFR: required before IV bisphosphonate dosing

— CBC, TSH: to exclude alternative ALP elevations (myeloproliferative, hyperthyroid bone turnover)

— Procollagen type 1 N-terminal propeptide (P1NP) and bone-specific ALP (BSAP) are more sensitive for monitoring when total ALP is normal or borderline, or when concurrent liver disease confounds total ALP

— Urine N-telopeptide (NTX) or serum CTX reflect osteoclastic resorption

— Lytic phase: "blade of grass" or "flame-shaped" advancing lucency in long bones; osteoporosis circumscripta in the skull

— Mixed phase: coarse trabecular thickening, cortical thickening, focal sclerosis intermixed with lysis

— Sclerotic/blastic phase: dense "cotton-wool" skull lesions, "picture-frame" vertebrae, ivory vertebra

— Pelvis: thickened iliopectineal and ilioischial lines, acetabular protrusion

— Bone enlargement (cortical thickening with expansion) — a key feature absent in metastatic disease

— Most sensitive test for mapping extent of polyostotic disease

— Intensely increased uptake in active lesions; identifies clinically silent sites that may need treatment

Board pearl: The diagnostic triad on Step 3 = elevated ALP + normal calcium/phosphate + characteristic radiographic appearance (cortical thickening, trabecular coarsening, bone enlargement). Bone biopsy is not needed for diagnosis unless imaging is atypical or sarcoma is suspected.

First-tier labs:

Bone turnover markers (specialty use):

Plain radiography — first imaging study for any symptomatic site:

Whole-body radionuclide bone scan (Tc-99m MDP):

Diagnostic Workup — Advanced and Confirmatory Studies

— Atypical radiographic features (pure lysis without sclerosis in older lesions, soft-tissue mass, cortical destruction)

— Sudden worsening pain or rising ALP in a stable patient → rule out sarcomatous transformation

— Neurologic symptoms referable to skull base or spine

— Pre-operative planning (hip/knee arthroplasty, osteotomy)

— Best for cortical detail, skull base anatomy, basilar invagination/platybasia, and fracture characterization

— Detects subtle cortical destruction concerning for osteosarcoma

— Indicated for spinal cord/nerve root compression, soft-tissue mass, or suspected malignant transformation

— Pagetic marrow shows fatty signal in chronic phase; malignancy shows replaced marrow with soft-tissue mass and cortical breach

— MRI brain/skull base for cranial neuropathies or hydrocephalus workup

— Order in any patient with skull involvement; documents baseline mixed conductive/sensorineural pattern and tracks progression on therapy

— If extensive skeletal involvement (>35–40%), warm skin over bones, wide pulse pressure, or HF signs — evaluate for high-output cardiac failure

— Not routine. Reserve for atypical lesions or to rule out malignancy

— Histology shows mosaic pattern of lamellar bone with prominent cement lines, abundant osteoclasts (large, hypernucleated, >20 nuclei), marrow fibrosis

— Suspicion: new soft-tissue mass, focal lytic destruction, dramatic pain escalation, rising ALP disproportionate to disease

— Workup: MRI of lesion, CT chest (mets), biopsy by orthopedic oncology

— Pagetic sarcoma carries a grim prognosis (5-yr survival <10%)

— Pagetic bone is expanded with thickened cortex; metastatic blastic lesions (prostate, breast) do not enlarge the bone and lack cortical thickening

— PSA, mammography, SPEP/UPEP in unclear cases

Key distinction: Bone enlargement + cortical thickening = Paget. Sclerotic mets, fibrous dysplasia, and lymphoma do not produce true cortical thickening with bone expansion.

When to go beyond plain films + bone scan:

CT:

MRI:

Audiometry:

Echocardiogram + BNP:

Bone biopsy:

Confirming sarcoma (osteosarcoma in 0.3–1% of pagetic patients):

Differentiating from metastases:

Risk Stratification and Treatment Indication Logic

— Symptomatic disease: bone pain attributable to active pagetic lesion, headache from skull involvement, radiculopathy

— Skull involvement (even if asymptomatic) — risk of hearing loss, cranial neuropathies, platybasia

— Weight-bearing long bones (femur, tibia) with lytic disease — fracture/deformity risk

— Vertebral involvement with risk of spinal stenosis or cord compression

— Periarticular disease near major joints — to limit secondary OA progression

— Preoperative before elective orthopedic surgery on pagetic bone — reduces intraoperative bleeding from hypervascularity

— Hypercalcemia of immobilization

— High-output cardiac failure attributable to disease

— Active disease in patients <40 (more aggressive course expected)

— Asymptomatic disease with markedly elevated ALP (>2× ULN) in high-risk anatomic sites

— Patient preference after shared decision-making

— Documented progressive deformity or rising markers

— Mildly elevated ALP in a stable asymptomatic non-weight-bearing site (e.g., iliac wing) in an older patient — observation with annual ALP is acceptable

— Normalize bone turnover (target: ALP into the normal range)

— Relieve pain, prevent complications (fracture, deformity, neurologic, hearing loss)

— Disease modification: durable suppression rather than lifelong continuous therapy

— Confirm 25-OH vitamin D ≥30 ng/mL and repletε if low

— Confirm eGFR ≥35 mL/min (for zoledronate)

— Dental exam before IV bisphosphonate (ONJ risk)

— Calcium intake counseling (1000–1200 mg/day)

— Baseline ALP and symptomatic-site imaging documented

Step 3 management: A 70-year-old with isolated iliac wing Paget, ALP 1.3× ULN, no symptoms → observation with annual ALP, not bisphosphonate. The same patient with skull involvement at the same ALP → treat, because of cranial neuropathy and hearing-loss risk.

Core question on Step 3: Not "does the patient have Paget?" but "does this patient need treatment?" Most patients are asymptomatic and many never require therapy.

Absolute / strong indications to treat (Endocrine Society 2014, still current):

Relative indications:

Not an indication by itself:

Goals of therapy:

Pre-treatment checklist (CCS-critical):

Pharmacotherapy — First-Line Bisphosphonate Therapy

— Strongest evidence base; superior biochemical response and longer remission than oral agents

— Achieves ALP normalization in ~90% of patients; median remission ~6 years, often longer

— Infuse over ≥15 minutes; ensure adequate hydration and vitamin D/calcium repletion beforehand

— Single dose often suffices; re-dose only when biochemical relapse occurs (ALP rises and exceeds normal, or symptoms recur)

— eGFR ≥35 mL/min (contraindicated below)

— 25-OH vitamin D ≥30 ng/mL — supplement 50,000 IU weekly × 2–4 weeks if low

— Calcium intake 1000–1200 mg/day; supplement during the first 2 weeks post-infusion

— Dental exam to mitigate ONJ risk

— Hold concurrent nephrotoxins; review NSAIDs, diuretics, ACEi

— Flu-like syndrome (fever, myalgia, arthralgia) in 25–40%, within 24–72 h of first infusion

— Pre-medicate or treat with acetaminophen; usually self-limited within 3 days

— Risk decreases with subsequent infusions

— Risedronate 30 mg daily × 2 months

— Alendronate 40 mg daily × 6 months

— Take on empty stomach with 8 oz water, remain upright 30–60 min; avoid in achalasia, esophageal stricture, inability to sit upright

— Lower ALP-normalization rates and shorter remission than zoledronate

— Largely replaced; reserve for patients intolerant of or contraindicated to all bisphosphonates

— Tachyphylaxis, weaker effect, modest pain relief

— Acetaminophen first-line; NSAIDs for inflammatory bony pain (caution renal, GI)

— Treat secondary OA pain separately — bisphosphonates do not fix established joint OA

— ALP at 6–12 weeks post-infusion, then at 6 months and annually

— Goal: ALP in the normal range; bone turnover markers (P1NP) if ALP is unreliable

Board pearl: The single most testable Paget treatment fact: IV zoledronic acid 5 mg once is first-line, but you must check vitamin D, calcium, and renal function first — and the patient gets a flu-like acute-phase reaction in roughly one-third of first infusions.

First-line agent: IV zoledronic acid 5 mg single infusion

Pre-infusion checklist (memorize for CCS):

Acute-phase reaction (very high-yield):

Oral bisphosphonate alternatives (if IV unavailable or refused):

Calcitonin (salmon, intranasal/subcut):

Adjunct analgesia:

Monitoring response:

Procedural and Surgical Management

— Pathologic or impending fracture of long bones (femur > tibia)

— Severe deformity causing functional impairment or gait disturbance (osteotomy)

— Secondary osteoarthritis of hip or knee unresponsive to medical therapy → arthroplasty

— Spinal cord/nerve root compression unresponsive to medical therapy

— Sarcomatous transformation — wide resection by orthopedic oncology

— Pre-operative IV zoledronate 5 mg several weeks before elective surgery on pagetic bone

— Rationale: pagetic bone is hypervascular → reduces intraoperative bleeding and may decrease heterotopic ossification and prosthesis loosening

— Optimize vitamin D and calcium beforehand

— Total hip arthroplasty for pagetic acetabular protrusion or severe secondary OA — generally good outcomes but higher rates of heterotopic ossification, intraoperative bleeding, and component loosening

— Pre-op planning CT helps with deformed anatomy

— Total knee replacement often requires custom or revision components due to bowing

— Corrective tibial or femoral osteotomy for severe bowing causing mechanical overload

— Performed by orthopedic surgery after biochemical suppression

— Indicated for confirmed cord/cauda equina compression

— Note: some "spinal stenosis" in Paget responds to bisphosphonates alone due to a vascular steal mechanism — trial medical therapy first when deficits are mild/non-progressive

— Chalk-stick (transverse) fractures of femur/tibia typical

— Surgical fixation often required; healing usually adequate but slower

— Initiate or resume bisphosphonate therapy post-fixation

— Multidisciplinary: orthopedic oncology, medical oncology, radiation

— Wide local excision ± chemotherapy; prognosis poor

CCS pearl: When a CCS stem describes an elective THA for "pagetic hip," the correct sequence is: labs (ALP, Ca, vitamin D, Cr) → vitamin D repletion → IV zoledronate ~4–6 weeks pre-op → dental clearance → surgery → resume monitoring ALP at 3 months. Skipping pre-op bisphosphonate is a graded misstep.

Indications for orthopedic surgery in PDB:

Perioperative bisphosphonate strategy (high-yield):

Joint arthroplasty considerations:

Osteotomy:

Spinal decompression:

Fracture management:

Sarcoma management:

Special Populations — Elderly and Renal/Hepatic Impairment

— Polypharmacy and fall risk dominate management

— Screen for vitamin D deficiency (very common) before any bisphosphonate

— Assess swallowing and ability to remain upright 30 min if oral bisphosphonate is chosen — frail elderly often fail this, favor IV route

— Cognitive screening if adherence with oral regimens is in question

— Bone density assessment for coexisting osteoporosis — many older patients have both; zoledronate covers both

— Zoledronate contraindicated if eGFR <35 mL/min

— Risedronate and alendronate: avoid if CrCl <30–35 mL/min

— In severe CKD (stage 4–5): consider calcitonin as bridging therapy, or carefully managed denosumab (not FDA-approved for Paget but used off-label; risk of severe hypocalcemia in CKD — requires aggressive calcium/vitamin D monitoring)

— Pre-infusion: hold ACEi/ARB/NSAID/diuretics if volume-depleted; hydrate with 500 mL NS before zoledronate

— Monitor creatinine 1–2 weeks post-infusion

— Bisphosphonates are renally cleared, not hepatically metabolized — generally safe

— Caveat: total ALP becomes unreliable as a monitoring tool with concurrent liver disease → use bone-specific ALP or P1NP instead

— A single dose of IV zoledronate treats both, but the dose differs:

— Paget: 5 mg once, then re-dose only on biochemical relapse

— Osteoporosis: 5 mg yearly

— Step 3 stems will test whether you know not to give "yearly zoledronate" automatically for a Paget patient — you treat Paget to durable remission, not on a calendar

— Calcium, iron, antacids, magnesium reduce oral bisphosphonate absorption — separate by 30–60 min

— Aminoglycosides + bisphosphonates → additive hypocalcemia risk

Step 3 management: A 78-year-old with Paget + eGFR 28 + vitamin D 18 ng/mL needs (1) vitamin D repletion, (2) calcium optimization, (3) avoid zoledronate; consider salmon calcitonin or specialist input regarding cautious denosumab. Document the renal contraindication explicitly.

Elderly (the modal Paget patient):

Renal impairment:

Hepatic impairment:

Concomitant osteoporosis:

Drug interactions:

Special Populations — Younger Adults, Pregnancy, and Familial Disease

— Uncommon; consider familial expansile osteolysis, juvenile Paget disease (TNFRSF11B mutation, OPG deficiency), and early-onset PDB with SQSTM1 mutations

— Disease tends to be more aggressive, polyostotic, and complication-prone

— Lower threshold to treat even mild disease

— Genetic counseling appropriate; consider screening first-degree relatives with serum ALP starting at age 40 (or 10 years before the proband's age of onset)

— Paget rarely presents in reproductive-age women, but the management question is testable

— Bisphosphonates are pregnancy category contraindicated/avoid — long skeletal half-life (~10 years) means residual drug persists in maternal skeleton; theoretical fetal skeletal toxicity in animal models

— Counsel women of reproductive potential on this before treatment; ideally complete therapy and allow washout before conception, though no specific interval is established

— If Paget is diagnosed during pregnancy: defer bisphosphonate; manage pain with acetaminophen; monitor calcium (immobilization risk)

— Breastfeeding: bisphosphonate excretion in milk unclear — generally avoid

— Juvenile Paget disease (idiopathic hyperphosphatasia): autosomal recessive OPG loss-of-function, presents in infancy/childhood with markedly elevated ALP, severe deformities, fractures, deafness

— Distinct from adult PDB; managed by pediatric endocrinology/genetics with cautious bisphosphonate therapy

— 15–40% have a family history; SQSTM1 mutations most consistently implicated

— Other genes: TNFRSF11A (RANK), VCP, OPTN

— Offer screening serum ALP in first-degree relatives of patients with early-onset or severe disease, starting at age 40 or a decade before the proband's onset

— Imaging only if ALP elevated or symptoms develop

— Document contraception plan in premenopausal women receiving bisphosphonates

— Discuss durability of skeletal drug retention

Board pearl: Bisphosphonate + pregnancy is a classic Step 3 trap — the correct answer is avoid and counsel about long skeletal half-life, not "switch to a different bisphosphonate." Plan therapy in non-pregnant women with explicit pre-conception discussion.

Young-onset Paget (<40 years):

Pregnancy and lactation:

Pediatrics:

Familial PDB:

Reproductive counseling:

Complications and Adverse Outcomes

— Fracture: especially transverse "chalk-stick" fractures of femur/tibia; stress fractures on the convex (tensile) surface of bowed long bones

— Deformity: anterolateral tibial bowing, lateral femoral bowing (shepherd's crook), skull enlargement, kyphosis

— Secondary osteoarthritis: the most common cause of pain in PDB — joints adjacent to pagetic bone develop accelerated OA, particularly hip and knee

— Acetabular protrusion → hip joint destruction

— Hearing loss (mixed conductive + sensorineural) — temporal bone, ossicles, cochlear capsule

— Cranial neuropathies (II, V, VII, VIII) from skull base foramen narrowing

— Platybasia/basilar invagination → brainstem compression, hydrocephalus

— Spinal stenosis with radiculopathy or myelopathy; vascular steal may cause cord ischemia even without mechanical compression

— High-output cardiac failure when ≥35–40% of skeleton involved (AV shunting in hypervascular bone)

— Increased prevalence of aortic stenosis and vascular calcification

— Hypercalcemia of immobilization when an actively pageting patient is bedridden (post-op, fracture)

— Hyperuricemia and gout (high bone turnover)

— Nephrolithiasis from chronic mild hypercalciuria

— Osteosarcoma in 0.3–1% of patients with PDB — typically pelvis, femur, humerus

— Giant cell tumor (rare, often skull or facial bones, more common in patients of Italian descent)

— Suspect with new soft-tissue mass, cortical destruction, sharp pain escalation, rising ALP disproportionate to disease

— Acute-phase reaction post-zoledronate (flu-like, 25–40%)

— Hypocalcemia if vitamin D deficient pre-infusion

— Osteonecrosis of the jaw (ONJ): rare at Paget doses

— Atypical femoral fractures: chronic suppressive bisphosphonate concern (less issue with episodic Paget dosing)

— Acute kidney injury with zoledronate if volume-depleted

Key distinction: Sudden focal pain escalation in known Paget = sarcoma until proven otherwise — urgent MRI ± biopsy, not a refill of analgesics.

Skeletal complications:

Neurologic complications:

Cardiovascular:

Metabolic:

Malignant transformation (rare but devastating):

Treatment-related complications:

When to Escalate Care — Consults and Inpatient Triage

— Suspected sarcomatous transformation (new mass, cortical destruction, escalating pain): urgent orthopedic oncology consult, MRI of lesion, CT chest

— Acute cord compression or cauda equina syndrome: STAT MRI, neurosurgery, high-dose dexamethasone, urgent decompression

— High-output cardiac failure with decompensation: diuresis, telemetry, cardiology consult, echocardiogram, BNP, address Paget activity with IV bisphosphonate once stabilized

— Symptomatic hypercalcemia of immobilization: IV fluids, calcitonin, IV bisphosphonate; admit if Ca >14 or symptomatic

— Pathologic fracture of weight-bearing long bone: orthopedic admission for fixation

— Acute basilar invagination with brainstem signs: neurosurgery emergent

— Endocrinology: new diagnosis with treatment decisions, biochemical relapse, atypical disease, young-onset, suspected familial disease

— Orthopedics: deformity, secondary OA needing arthroplasty, fracture risk

— Orthopedic oncology: suspected sarcoma

— Neurosurgery: cord compression, basilar invagination, intractable headache from skull disease

— ENT/audiology: hearing loss, baseline and follow-up audiograms with skull disease

— Dental: mandatory clearance before IV bisphosphonate

— Cardiology: suspected high-output failure

— Genetics: young-onset or familial pattern, juvenile Paget

— Asymptomatic, mild ALP elevation, low-risk anatomic site, stable on annual monitoring

— Post-zoledronate patient with normalized ALP — annual ALP and clinic visit

— New neurologic deficit

— Sudden severe pain

— Hearing change

— Symptoms of HF in known extensive disease

CCS pearl: A CCS stem with "65-year-old with known pelvic Paget, now with rapidly enlarging thigh mass and ALP that doubled in 3 months" — your immediate orders are MRI thigh with contrast, CT chest, orthopedic oncology consult, biopsy planning — not "increase bisphosphonate." Missing sarcoma is the single most consequential cognitive error in this disease.

Emergent inpatient admission warranted for:

Subspecialty consults — outpatient or inpatient:

Outpatient stable management — primary care can lead when:

Patient red flags warranting same-week eval:

Key Differentials — Other Causes of Elevated ALP and Lytic/Sclerotic Bone Lesions

— ALP elevated, calcium HIGH, phosphate low, PTH elevated

— Radiographs: subperiosteal resorption, brown tumors, salt-and-pepper skull — no bone enlargement, no cortical thickening

— Key lab: PTH

— ALP elevated, calcium low-normal or low, phosphate low, 25-OH vitamin D low, PTH high (secondary)

— Radiographs: Looser zones (pseudofractures), generalized osteopenia

— No focal sclerosis or cortical expansion

— Setting: advanced CKD

— Mixed picture (high turnover with hyperparathyroidism or adynamic bone), elevated phosphate, low calcium, elevated PTH

— Vascular calcifications prominent

— Young patient, monostotic or polyostotic, "ground glass" matrix, "shepherd's crook" femur (overlap with Paget!)

— McCune-Albright triad: polyostotic fibrous dysplasia + café-au-lait + precocious puberty

— GNAS mutation; ALP can be elevated but patient is younger and lesions are typically ground-glass, not coarse trabeculae

— Sclerotic foci but no bone enlargement, no cortical thickening

— Often multiple discrete lesions; PSA in men, mammography in women

— Bone scan: discrete hot spots vs Paget's coalescent, bone-shaped pattern

— Multiple punched-out lesions

— Myeloma: SPEP/UPEP, free light chains, anemia, hypercalcemia, renal failure, normal-to-low ALP

— Solitary plasmacytoma can mimic a pagetic lesion

— Dense diffuse sclerosis, pancytopenia, cranial nerve palsies, "bone-within-bone" appearance

— Genetic; usually young patients

Key distinction: Among ALP-elevation differentials, only Paget produces bone enlargement with cortical thickening on imaging while calcium and phosphate remain normal. Always anchor on this triad.

Hyperparathyroidism (primary):

Osteomalacia/vitamin D deficiency:

Renal osteodystrophy:

Fibrous dysplasia:

Sclerotic metastases (prostate, breast, lymphoma):

Lytic metastases (renal, thyroid, lung, multiple myeloma):

Osteopetrosis:

Key Differentials — Non-Bony Causes of Elevated ALP

— Cholestasis: primary biliary cholangitis, primary sclerosing cholangitis, bile duct obstruction, drug-induced cholestasis

— GGT will be elevated when ALP is hepatic in origin; normal GGT supports bony source

— LFTs typically abnormal; bilirubin may be elevated

— RUQ ultrasound if hepatic source suspected

— Placental ALP physiologically elevated in 2nd–3rd trimester (heat-stable isoenzyme)

— No workup needed if otherwise asymptomatic

— Bone-growth ALP physiologically elevated during growth spurts and rapid skeletal accrual

— Confused with disease only if extreme

— Bone turnover increased → mildly elevated ALP

— TSH, free T4 to screen

— ALP rises during callus formation and normalizes over weeks–months

— History clarifies

— Anticonvulsants (phenytoin, carbamazepine, phenobarbital) — induce hepatic ALP and disturb vitamin D metabolism

— Estrogens, oral contraceptives — cholestatic pattern

— Antibiotics (amoxicillin-clavulanate), antifungals

— Vitamin D deficiency raises ALP (secondary hyperparathyroidism, osteomalacia)

— Always check 25-OH vitamin D in any unexplained ALP elevation

— Sarcoidosis with bone involvement (small punched-out phalangeal lesions)

— Hematologic malignancies with marrow infiltration

— Renal osteodystrophy as above

1. Repeat ALP, confirm sustained

2. GGT (and/or 5'-nucleotidase, fractionated ALP isoenzymes) → hepatic vs bony

3. If hepatic: full LFTs, RUQ ultrasound, autoimmune liver panel

4. If bony: calcium, phosphate, PTH, 25-OH D, plain radiographs of symptomatic sites, then bone scan if Paget pattern suspected

Board pearl: The single best confirmatory next step when ALP is elevated and you suspect bone is the source is to check GGT — normal GGT excludes hepatic origin and points decisively toward bone, justifying skeletal imaging.

Hepatobiliary disease (most common alternative source):

Pregnancy:

Childhood/adolescence:

Hyperthyroidism:

Healing fracture:

Drugs:

Vitamin deficiencies:

Less common bony causes confused with Paget:

Diagnostic algorithm for isolated ALP elevation:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Sustain biochemical remission (ALP in normal range)

— Prevent fracture, deformity progression, hearing loss, secondary OA, sarcoma surveillance

— Address comorbid osteoporosis, fall risk, vitamin D status

— Calcium 1000–1200 mg/day (diet + supplement as needed)

— Vitamin D 800–2000 IU/day, titrated to 25-OH vitamin D ≥30 ng/mL

— Adequate hydration, especially around bisphosphonate dosing

— Most patients achieve multi-year remission after one zoledronate infusion — do not re-dose by calendar, re-dose on biochemical or clinical relapse

— Definition of biochemical relapse: ALP rises and exceeds the upper limit of normal, or rises >25% from nadir, or symptoms recur

— Some specialists target bone-specific ALP or P1NP for relapse detection

— Acetaminophen first-line

— NSAIDs short-term (caution renal, GI, CV)

— Treat secondary OA pain with PT, intra-articular injections, weight optimization, eventual arthroplasty

— Refer for chronic pain management if multimodal

— Home safety assessment, lighting, grab bars, remove rugs

— Vision and hearing optimization

— Strength and balance training, physical therapy

— Medication reconciliation to remove fall-risk drugs

— Baseline audiogram in any skull disease

— Treat active disease promptly to halt progression

— Hearing aid referral when indicated

— Educate patient: report new pain, swelling, mass in known pagetic bone immediately

— No routine imaging surveillance recommended in asymptomatic patients

— DXA at diagnosis if age and risk warrant

— Single zoledronate dose treats both; subsequent dosing tailored to dominant problem

Step 3 management: At discharge after a Paget-related femoral fixation, your medication list must include calcium, vitamin D 1000–2000 IU, acetaminophen PRN, DVT prophylaxis, and a scheduled IV zoledronate infusion as outpatient once dental clearance and vitamin D repletion are confirmed — plus PT referral and orthopedic follow-up in 2 weeks.

Goal of long-term care:

Standing supportive medications (every Paget patient):

Disease-modifying therapy plan:

Pain management:

Fall prevention (these patients are elderly with bowed bones):

Hearing preservation:

Surveillance for sarcoma:

Comorbid osteoporosis:

Follow-Up, Monitoring Parameters, and Counseling

— ALP at 6–12 weeks after zoledronate (early response signal)

— ALP at 6 months — should approach or reach the normal range

— ALP annually thereafter — relapse detection

— Symptom check, neurologic and functional assessment at each visit

— Repeat imaging only for symptom recurrence, new neurologic finding, or suspicion of complication — no routine annual films

— Therapeutic response: ALP normalization within 6 months (achieved in ~90% with IV zoledronate)

— Biochemical relapse: ALP rises above ULN, or >25% above nadir

— Re-treat with another zoledronate infusion when relapse occurs; intervals of several years are typical

— Patients with skull involvement: audiogram every 1–2 years or with symptoms

— Patients with spinal involvement: neurologic exam at each visit; MRI only with new deficit

— Patients with weight-bearing long bone disease: monitor for bowing progression and gait change

— Annual ALP and symptom check

— Treat if ALP rises significantly, symptoms develop, or disease extends to a higher-risk site

— Disease is not curable but highly controllable

— Most patients live a normal lifespan; sarcoma is rare

— Importance of calcium, vitamin D, exercise, fall prevention

— Recognize warning signs: new pain or swelling, hearing change, neurologic symptoms

— Dental hygiene before any future bisphosphonate

— PT for gait training, strengthening, balance

— OT for ADL adaptation in patients with deformity

— Orthotics for leg-length discrepancy

— Hearing aids as needed

— Standard adult vaccinations; pneumococcal and influenza in elderly

— Cancer screening per age guidelines (don't let Paget overshadow USPSTF basics)

CCS pearl: When a CCS Paget patient returns at 6 months, the orders that score are ALP, calcium, creatinine, vitamin D, symptom assessment, and medication reconciliation — not "repeat bone scan." Imaging is symptom-driven, not surveillance-driven, in stable Paget.

Post-treatment monitoring schedule:

Defining response and relapse:

Long-term tracking:

Asymptomatic untreated patients:

Patient counseling points:

Rehabilitation:

Vaccination and general preventive care:

Ethical, Legal, and Patient Safety Considerations

— Disclose: acute-phase flu-like reaction (~30% of first infusions), rare osteonecrosis of the jaw, rare atypical femoral fracture, hypocalcemia risk, AKI risk, infusion reaction

— Discuss expected durability (years of remission) so patients understand this is not a lifelong daily medication

— Document vitamin D, calcium, renal function, and dental clearance in the chart before infusion — these are frequently audited safety steps

— Women of reproductive potential must be counseled on the decade-long skeletal half-life and theoretical fetal risk

— Documented shared decision-making is the safety standard; offer contraception planning

— Patient discharged after pagetic fracture fixation needs explicit outpatient zoledronate scheduling, vitamin D follow-up labs, PT referral, and a clear PCP hand-off note — dropped hand-offs are a recurring safety failure

— Communicate "no further zoledronate by calendar" plan to prevent inadvertent annual re-dosing by an osteoporosis-minded provider

— Document dental exam before IV bisphosphonate

— Advise patients to inform any future dentist of bisphosphonate exposure (lifelong disclosure, given skeletal retention)

— Hearing loss disclosure for occupational fitness (commercial driving, aviation) where relevant

— Document falls and report per institutional patient-safety processes

— Elderly Paget patients may develop cognitive impairment; ensure advance directives and surrogate identification, especially before any orthopedic surgery

— IV zoledronate is generally less expensive cumulatively than years of oral bisphosphonate when remission durability is considered — relevant for value-based care discussions

— Address insurance authorization proactively; document medical necessity (symptomatic disease, high-risk site)

— Treating asymptomatic low-risk Paget purely because ALP is mildly elevated is low-value care — Endocrine Society guidance supports observation in select cases. Document the rationale for not treating.

Board pearl: The most testable safety pearl: dental clearance + vitamin D repletion + renal function check before IV bisphosphonate. Skipping any of these on a CCS case is a graded patient-safety error, even if the patient does well.

Informed consent for IV zoledronate (Step 3-flavored):

Reproductive counseling and bisphosphonate retention:

Transition-of-care safety risks (high Step 3 yield):

Dental ONJ prevention:

Mandatory communication:

Surrogate decision-making:

Cost and access:

Avoiding overtreatment:

High-Yield Associations and Rapid-Fire Clinical Facts

— SQSTM1/p62 — most common gene

— TNFRSF11A (RANK) — familial expansile osteolysis

— TNFRSF11B (OPG) — juvenile Paget

— VCP — inclusion body myopathy + Paget + frontotemporal dementia (IBMPFD)

— Northern European ancestry; UK historically highest

— Age >55, slight male predominance

— Declining incidence globally over recent decades

— Cotton-wool skull

— Osteoporosis circumscripta (early lytic skull)

— Blade of grass / flame-shaped lytic front in long bones

— Picture-frame vertebra / ivory vertebra

— Saber shin tibia, shepherd's crook femur

— Tam o' Shanter sign (skull hangs over face)

— Mosaic pattern of lamellar bone on biopsy

— Older adult, enlarging hat size, hearing loss, bowed tibia, warmth over bone, chalk-stick fracture, deep night-time bone pain

Key distinction: Among sclerotic bone diseases, only Paget enlarges the bone with cortical thickening while keeping calcium and phosphate normal — anchor every differential question on this.

Genetics:

Demographics:

Most common sites (rapid recall): Pelvis > spine (lumbar) > femur > skull > tibia

Lab signature: Elevated ALP, normal calcium, normal phosphate, normal GGT, P1NP elevated, NTX/CTX elevated

Imaging buzzwords:

Clinical buzzwords:

Cardiac association: high-output failure when >35–40% skeletal involvement

Malignant transformation: <1%, osteosarcoma > giant cell tumor; sudden pain escalation is the key clue

First-line drug: IV zoledronic acid 5 mg once

Pre-treatment checklist: vitamin D, calcium, renal function, dental exam

Monitoring: ALP at 6–12 weeks, 6 months, then annually

Acute-phase reaction: ~30%, flu-like, 24–72 h, treat with acetaminophen

Bisphosphonate pregnancy issue: decade-long skeletal half-life → avoid in women planning pregnancy; counsel explicitly

Don't treat just because: asymptomatic, low-risk site, modest ALP elevation → observe with annual labs

Treat because: symptoms, skull, weight-bearing long bone, near joint, vertebral, preoperative, immobilization hypercalcemia, high-output HF

Board Question Stem Patterns

"68-year-old man, routine labs: ALP 412 (normal <120), Ca 9.4, Phos 3.5, normal LFTs, normal GGT. Asymptomatic."

— Next step: plain radiographs of pelvis/hips and lumbar spine, then bone scan to map extent. Treat only if symptoms or high-risk site (skull, weight-bearing long bone, vertebral, periarticular).

"72-year-old woman with anterior tibial bowing, warmth over the bone, deep pain worse at night, ALP elevated, normal calcium."

— Diagnosis: Paget. Treatment: IV zoledronate after checking vitamin D, calcium, renal function, dental exam.

"70-year-old man, progressive hearing loss, hats no longer fit, headache. ALP 580. Skull film shows 'cotton-wool' appearance."

— Diagnosis: skull Paget. Action: treat (skull involvement is always an indication), audiogram baseline, neurologic exam for cranial nerves and basilar invagination.

"66-year-old with extensive Paget, now with dyspnea, wide pulse pressure, warm extremities, S3, BNP elevated."

— Diagnosis: high-output HF from AV shunting in pagetic bone. Action: diuresis + IV zoledronate to reduce vascularity.

"Known pelvic Paget on observation, now with sharp escalating thigh pain, palpable mass, ALP doubled."

— Diagnosis: osteosarcoma transformation. Action: MRI, CT chest, orthopedic oncology, biopsy.

"Paget patient scheduled for total hip arthroplasty for acetabular protrusion."

— Action: pre-op IV zoledronate several weeks prior to reduce bleeding, optimize vitamin D, dental clearance.

"Transverse mid-femoral fracture in a 70-year-old with bowed femur and elevated ALP."

— Diagnosis: pagetic chalk-stick fracture. Action: orthopedic fixation, then zoledronate.

"Paget patient with eGFR 25 needs treatment for symptomatic skull disease."

— Action: zoledronate contraindicated; consider salmon calcitonin or specialist input.

"35-year-old woman with early-onset Paget, planning pregnancy."

— Action: avoid bisphosphonate, counsel on skeletal half-life, manage symptomatically; consider treatment timing relative to family planning.

Board pearl: When the stem gives you isolated ALP + normal Ca/Phos + older patient, your two reflex orders are GGT (confirm bone source) and plain radiograph of any symptomatic site, followed by bone scan. This sequence is almost always rewarded.

Stem 1 — Incidental ALP elevation:

Stem 2 — Bowed tibia + warmth:

Stem 3 — Hearing loss + enlarging hat:

Stem 4 — High-output failure:

Stem 5 — Sudden severe pain in known Paget:

Stem 6 — Pre-op for THA:

Stem 7 — Chalk-stick fracture:

Stem 8 — Renal impairment:

Stem 9 — Pregnancy:

One-Line Recap

Paget disease of bone is a focal disorder of accelerated, disorganized bone remodeling that classically presents in older adults as isolated alkaline phosphatase elevation with normal calcium and phosphate, characteristic radiographic bone enlargement with cortical thickening, and is treated — when symptomatic or affecting high-risk sites — with a single dose of IV zoledronic acid 5 mg after vitamin D, calcium, renal function, and dental clearance have been confirmed.

— Elevated ALP + normal Ca/Phos + normal GGT + bone enlargement on imaging = Paget

— Plain radiographs of symptomatic sites first; whole-body bone scan to map extent

— Bone biopsy not needed unless atypical features or suspected sarcoma

— Treat for: symptoms, skull, weight-bearing long bones, vertebrae, periarticular sites, pre-op, immobilization hypercalcemia, high-output HF

— IV zoledronate 5 mg once — re-dose only on biochemical or clinical relapse, not by calendar

— Pre-treatment: 25-OH vitamin D ≥30, eGFR ≥35, dental exam, calcium intake adequate

— Expect ~30% acute-phase flu-like reaction; treat with acetaminophen

— ALP at 6–12 weeks, 6 months, then annually

— Relapse = ALP rises above ULN or >25% above nadir

— Imaging only for symptom recurrence or new neurologic findings

— Sarcomatous transformation (<1%) — new mass, sudden pain, rising ALP → MRI + ortho-onc

— Cord compression, basilar invagination, high-output HF, chalk-stick fracture, hearing loss

— Address comorbid osteoporosis, fall risk, secondary OA in parallel

Step 3 management: Anchor every Paget vignette on three reflexes — confirm bony origin (GGT), define extent (bone scan), and decide treatment by site and symptoms, not by ALP number alone.

Diagnosis pearls:

Treatment pearls:

Monitoring pearls:

Don't-miss complications: